RS51125B - Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja - Google Patents

Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja

Info

Publication number
RS51125B
RS51125B YUP-578/03A YUP57803A RS51125B RS 51125 B RS51125 B RS 51125B YU P57803 A YUP57803 A YU P57803A RS 51125 B RS51125 B RS 51125B
Authority
RS
Serbia
Prior art keywords
inhibitors
prevention
treatment
heart disease
inhibitor
Prior art date
Application number
YUP-578/03A
Other languages
English (en)
Inventor
Charles Dinarello
Benjamin Pomerantz
Leonid Reznikov
Alden Harken
Yolande Chvatchko
Original Assignee
Laboratoires Serono Sa.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono Sa. filed Critical Laboratoires Serono Sa.
Publication of YU57803A publication Critical patent/YU57803A/sh
Publication of RS51125B publication Critical patent/RS51125B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Upotreba inhibitora IL-18 u proizvodnji leka za terapiju i/ili prevenciju kardiomiopatije, naznačeno time da inhibitor IL-18 se bira između inhibitora kaspaze-1 (ICE), antitela protiv IL-18, antitela protiv ma koje od IL- 18 receptorskih podjedinica, i IL-18 vezujućih proteina, ili izoforma, muteina, spojenih (fuziranih) proteina, ili njihovih funkcionalnih derivata koji inhibiraju biološku aktivnost IL-18. Prijava sadrži još 2 nezavisna i 14 zavisnih patentnih zahteva.
YUP-578/03A 2001-01-29 2002-01-28 Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja RS51125B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29

Publications (2)

Publication Number Publication Date
YU57803A YU57803A (sh) 2006-05-25
RS51125B true RS51125B (sr) 2010-10-31

Family

ID=8176323

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-578/03A RS51125B (sr) 2001-01-29 2002-01-28 Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja

Country Status (32)

Country Link
US (1) US20040234523A1 (sr)
EP (1) EP1355668B1 (sr)
JP (2) JP4860897B2 (sr)
KR (1) KR100857376B1 (sr)
CN (1) CN1326562C (sr)
AR (1) AR032422A1 (sr)
AT (1) ATE380558T1 (sr)
BG (1) BG66483B1 (sr)
BR (1) BR0206819A (sr)
CA (1) CA2435466C (sr)
CY (1) CY1107203T1 (sr)
CZ (1) CZ305653B6 (sr)
DE (1) DE60224004T2 (sr)
DK (1) DK1355668T3 (sr)
EA (2) EA010180B1 (sr)
EE (1) EE05534B1 (sr)
ES (1) ES2295332T3 (sr)
HK (1) HK1062810A1 (sr)
HR (1) HRP20030609A2 (sr)
HU (1) HU229164B1 (sr)
IL (2) IL157024A0 (sr)
ME (1) ME00549B (sr)
MX (1) MXPA03006776A (sr)
NO (1) NO331083B1 (sr)
PL (1) PL213568B1 (sr)
PT (1) PT1355668E (sr)
RS (1) RS51125B (sr)
SI (1) SI1355668T1 (sr)
SK (1) SK287620B6 (sr)
UA (1) UA80676C2 (sr)
WO (1) WO2002060479A1 (sr)
ZA (1) ZA200305439B (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001236807A1 (en) 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
WO2002031115A2 (en) 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
JP5091127B2 (ja) 2005-06-10 2012-12-05 アレス トレーディング ソシエテ アノニム Ｉｌ−１８結合タンパク質の精製のための方法
WO2009061832A1 (en) * 2007-11-05 2009-05-14 Kci Licensing Inc. Identification of tissue for debridement
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MX2016002719A (es) * 2013-09-05 2016-09-06 Ab2 Bio Sa Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias.
EP3265807A1 (en) 2015-03-05 2018-01-10 AB2 Bio SA Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
WO2018013509A1 (en) * 2016-07-11 2018-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
ATE310528T1 (de) * 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
ATE346085T1 (de) * 1996-12-06 2006-12-15 Vertex Pharma Inhibitoren des interleukin-1-beta konvertierenden enzyms
KR20000076420A (ko) * 1997-03-18 2000-12-26 스타르크, 카르크 코르티코스테로이드에 대한 반응성을 조절하기 위한 방법 및 조성물
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
EP1110969A4 (en) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18 BINDING PROTEIN
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
EP1165490B1 (en) * 1999-03-16 2006-08-16 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
ATE363465T1 (de) * 1999-04-09 2007-06-15 Cytovia Inc Caspase inhibitoren und ihre verwendung
WO2001003719A2 (en) * 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
AU2001236807A1 (en) * 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
DE60134009D1 (de) * 2000-05-05 2008-06-26 Inst Nat Sante Rech Med Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
UA80676C2 (en) 2007-10-25
IL157024A (en) 2014-02-27
KR20030070143A (ko) 2003-08-27
SK287620B6 (sk) 2011-04-05
EA200501549A1 (ru) 2006-04-28
ME00549B (me) 2011-10-10
MXPA03006776A (es) 2003-10-24
ZA200305439B (en) 2004-07-15
DE60224004D1 (de) 2008-01-24
HUP0303306A3 (en) 2005-12-28
BG108128A (bg) 2004-11-30
US20040234523A1 (en) 2004-11-25
AR032422A1 (es) 2003-11-05
EP1355668B1 (en) 2007-12-12
JP2009102354A (ja) 2009-05-14
HK1062810A1 (en) 2004-11-26
EA006767B1 (ru) 2006-04-28
IL157024A0 (en) 2004-02-08
HUP0303306A2 (hu) 2004-01-28
CN1499982A (zh) 2004-05-26
WO2002060479A1 (en) 2002-08-08
EP1355668A1 (en) 2003-10-29
SI1355668T1 (sl) 2008-06-30
SK10892003A3 (sk) 2004-02-03
BR0206819A (pt) 2004-02-03
CZ20032335A3 (en) 2004-07-14
CN1326562C (zh) 2007-07-18
PT1355668E (pt) 2008-01-04
EA200300844A1 (ru) 2003-12-25
CA2435466C (en) 2012-04-03
HRP20030609A2 (en) 2005-06-30
KR100857376B1 (ko) 2008-09-05
JP2004522748A (ja) 2004-07-29
BG66483B1 (bg) 2015-03-31
DK1355668T3 (da) 2008-05-05
NO20033228D0 (no) 2003-07-16
ATE380558T1 (de) 2007-12-15
CA2435466A1 (en) 2002-08-08
ES2295332T3 (es) 2008-04-16
EA010180B1 (ru) 2008-06-30
HU229164B1 (en) 2013-09-30
PL213568B1 (pl) 2013-03-29
JP4860897B2 (ja) 2012-01-25
NO331083B1 (no) 2011-10-03
DE60224004T2 (de) 2009-07-23
EE05534B1 (et) 2012-04-16
PL366802A1 (en) 2005-02-07
NO20033228L (no) 2003-09-26
CY1107203T1 (el) 2012-11-21
YU57803A (sh) 2006-05-25
CZ305653B6 (cs) 2016-01-27
EE200300328A (et) 2003-10-15

Similar Documents

Publication Publication Date Title
RS51755B (sr) Korišćenje inhibitora il-18 za lečenje i/ili prevenciju perifernih vaskularnih bolesti
RS51125B (sr) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
IS7431A (is) Samrunaefnasambönd lyfja eða frumudrepandi efna og líffræðilega virkra peptíða
DE60322436D1 (de) Verabreichung von capsaicinoiden
SE9800836D0 (sv) New Compounds
CY1114420T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση που περιλαμβανει καλσιποτριολη και βηταμεθαζονη για την αγωγη της ψωριασης
BRPI0411924A (pt) métodos e dispositivos para oclusão de lúmens de corpo e/ou para fornecimento de agentes terapêuticos
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
SE0302488D0 (sv) New combination
TW200507829A (en) New combination
RS51041B (sr) Tečne formulacije tbp-1 proteina koji vezuju faktor tumorske nekroze
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
MXPA02006511A (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
MY134059A (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
RS50681B (sr) Kombinacija taksana i ciklin-zavisne kinaze
NO995692D0 (no) Nye BPC-peptidsalter med organbeskyttende aktivitet, metoden for deres fremstilling og deres anvendelse
DK1399186T3 (da) Lægemiddel til behandling af tumorer og disses metastaser under anvendelse af et bindemolekyle mod knogle-sialoprotein
FR2842527B1 (fr) Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique
DE60119347D1 (de) Verwendung von chimäres il6-il6r in huntingtonskrankheit
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
SE0202608D0 (sv) New sequences